FDA’s Recent Actions Against Illegal Prescription Drug Flow

Alexis Brekke Pellek PharmTech editorLast month, US Food and Drug Administration Commissioner Margaret Hamburg announced the agency’s six-point plan for tougher enforcement of its policies and regulations as means of protecting public health. The plan, which includes actions like setting postinspection deadlines, speeding the Warning Letter process, and working more closely with FDA’s regulatory partners, was designed to “to prevent harm to the American people,” as Hamburg said in an FDA release. 

The agency has been actively involved in several recent cases involving instances of illegal importation and sales, drug diversion, and misbranding of drug products. Read more »

Can Insurance Companies Help Improve Health?

Angie Drakulich PharmTech editorUnitedHealth Group, a Minneapolis-based healthcare company, recently announced that it would soon provide a price break to members who correctly use certain asthma and antidepressant drugs. The news was reported in a Wall Street Journal article by Peter Loftus of Dow Jones Newswires.  

To get the $20 copay discount, members must refill their prescriptions within about 30 days after their last prescription runs out. Eligible drugs include GlaxoSmithKline’s Advair, AstraZeneca’s Symbicort, Eli Lilly’s Cymbalta, Wyeth’s Effexor XR, and Wyeth’s Pristiq. The discount applies to members who have a normal copay of $50 on these drugs, meaning the new copay would be $30, according to Loftus’ article. Read more »

Chutes, Ladders, and Healthcare Reform

Erik Greb PharmTech editorCongress has taken up the Obama administration’s goal of making healthcare more affordable by introducing various strategies for reducing the cost of prescription drugs. But the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization (BIO) have resisted several of Congress’s initiatives, and cost control has been elusive so far. Read more »

Fighting Drug Abuse with Drug Delivery

Erik Greb PharmTech editorReports of teenagers’ pharm parties, Rush Limbaugh’s OxyContin addiction, and the questions surrounding Michael Jackson’s death have kept prescription-drug abuse in the public eye. By requiring manufacturers of opioid drugs to create risk evaluation and mitigation strategies, the US Food and Drug Administration is seeking to reduce opportunities for drug abuse while keeping the therapies available to patients who need them. One pharmaceutical company suggests that, in addition to regulatory solutions, drug abuse could be curbed using drug-delivery strategies. Read more »

The Gathering Storm of Generics

Erik Greb PharmTech editorLike a snowball that gets bigger and bigger as it hurtles down the side of a mountain, generic drugs pose an increasingly large threat to branded pharmaceutical companies. Wolters Kluwer Health’s annual analysis reveals that more than 60% of all US prescriptions filled in 2008 were generics. For orally administered medicines, the percentage was even greater. In 2008, 2.4 billion prescriptions were filled for generic drugs, and only 1.4 billion for branded therapies—an unprecedented divide, according to the report.

What’s Big Pharma to do? Read more »

Cutting Costs, but Not at Patients’ Expense

Erik Greb PharmTech editorMany state legislatures are looking for ways to keep their healthcare costs down. Given our difficult economy, attempts at fiscal prudence do not come as a surprise. What’s heartening is that many states’ bills draw a link between healthcare expenses and doctor–patient confidentiality. Read more »

Should Thinning Wallets Equal Untreated Illnesses?

Angie Drakulich PharmTech editorTwo new studies highlight the steps-some of them too risky-that patients are taking to protect their pockets from totally emptying.

One study from the Center for Studying Health System Change reports that one in seven children and working-age Americans went without a prescription drug in 2007 because of cost concerns. Read more »

Helping Patients in Dire Financial Straits

Erik Greb PharmTech editorPharmaceutical Technology focuses much of its attention on the companies that manufacture the world’s drugs. We’ve noticed many stories on the wires lately that describe how the current economic situation is hurting drugmakers. But several press releases I saw today reminded me that patients are experiencing difficult times, too. Read more »

Speaking with Actions or Words?

Erik Greb PharmTech editorNew Hampshire’s 2006 “Prescription Information Law” raised questions about the boundaries between speech, actions, and privacy. Last week, the First US Circuit Court of Appeals answered those questions by ruling that the law is constitutional. The ruling overturned a 2007 US District Court decision. Read more »

Poor Economy Affects Pharma in Many Ways: Here’s One

Angie Drakulich PharmTech editorI have another radio story to share with you….driving to work the other day, I heard a report that 11% of US consumers have cut back on the number of prescription drugs they take or on the dosage of those medications in order to make the prescriptions last longer. Read more »